• 93
  • 11
  • 收藏

Scottish biotech TC BioPharm lowers deal size by 40%, adds warrants ahead of $30 million US IPO

Renaissance Capital2021-12-25

TC BioPharm Holdings, a Scottish Phase 2 biotech developing allogeneic gamma-delta T cell therapies, lowered the proposed deal size for its upcoming IPO on Thursday. The Holytown, UK-based company now...

网页链接

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

举报

评论11

  • etan000
    ·2021-12-26
    Ok
    回复
    举报
  • SeanSak
    ·2021-12-26
    Like n comment
    回复
    举报
  • sfleong1
    ·2021-12-26
    Like n comment
    回复
    举报
  • KeeBoonTong
    ·2021-12-26
    Lalala
    回复
    举报
    收起
  • Zivcheah
    ·2021-12-26
    O
    回复
    举报
    收起
    • Zivcheah
      O
      2021-12-26
      回复
      举报
  • matcha_latte
    ·2021-12-26
    Ok
    回复
    举报
  • 3eb0d2e3
    ·2021-12-26
    Ok
    回复
    举报
    收起
    • 3eb0d2e3
      k
      2021-12-26
      回复
      举报
  • lynnnn
    ·2021-12-26
    .
    回复
    举报
    收起
    • lynnnn
      [What]
      2021-12-26
      回复
      举报
  • Michane
    ·2021-12-25
    Stocks aside, CAR-T technology is a really good medical advancement for cancer patients. Hope that the trials with TC BioPharm are a great success!
    回复
    举报
    收起
  • andrewtingg
    ·2021-12-25
    Like
    回复
    举报
    收起
    • LEEYQ
      like
      2021-12-25
      回复
      举报
  • andrewtingg
    ·2021-12-25
    Like
    回复
    举报
    收起
 
 
 
 

热议股票

 
 
 
 
 

7x24